Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Ceritinib and ribociclib in ALK-positive NSCLC

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 24.10.18
Views: 1396

Dr Enriqueta Felip - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

Dr Enriqueta Felip speaks with ecancer at ESMO 2018 in Munich about a study assessing certinib and ribociclib in patients with ALK-positive NSCLC.

Dr Felip reveals that, following positive results, there are a number of agents available in first-line.

Dr Felip also spoke about other lung cancer news from the conference, here.

ecancer's filming has been kindly supported by MSD through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

22.11.18

no rating
Remembering Prof Arti Hurria

follow us

BGICC conference


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation